Ajit Narang
Senior Principal Scientist
Genentech
Ajit Narang works for Small Molecule Pharmaceutical Sciences at Genentech, Inc., in South San Francisco, CA as a Sr. Scientist responsible for the pharmaceutics and biopharmaceutics of small molecules in preclinical and early clinical development of various dosage forms. He also serves as • Scientific Advisor to the Editors of JPharmSci • Chair of the Formulation Design and Delivery (FDD) section of the American Association of Pharmaceutical Scientists (AAPS) • Adjunct Faculty at the Universities of the Pacific and the University of Nebraska Medical Center in Omaha, NE; • Industrial Advisory Board member of Western Michigan University; • A panel member of the Biopharmaceutics Technical Committee (BTC) of the Pharmaceutical Quality Research Institute (PQRI) in Arlington, VA; • Several International Pharmaceutics Excipient Council (IPEC) committees; and • A member of the Systems-based Pharmaceutics (SBP) alliance of the Process Systems Enterprise, Inc. (PSE) in London, UK • Committee member of a Master’s student at Campbell University, North Carolina; • Committee member of a Ph.D. student at University of Nebraska Medical Center, Omaha, NE. • Scientific Advisor to the Editors of JPharmSci Ajit earned his Ph.D. from the University of Tennessee in Memphis, Masters in Pharmaceutics from the Banaras Hindu University in India, and Bachelors in Pharmaceutical Sciences from the University of Delhi in India. He has over 15 years of drug product development experience working for Bristol-Myers Squibb, Co. (BMS) in New Jersey, Wockhardt Pharmaceuticals (ex-Morton Grove Pharmaceuticals) in Illinois, and Ranbaxy Research Labs in India in different capacities. Ajit has contributed to several preclinical, clinical, and commercialized drug products including NDAs, ANDAs, and 505B2s. He is credited with over 74 peer-reviewed articles; 4 books; 9 issued patents/patent applications; 43 invited talks; and 83 presentations at various scientific meetings. His current research interests are translation from preclinical to clinical and commercial drug product design; incorporation of QbD elements in drug product development; and mechanistic understanding of the role of material properties on product performance.